American Alpha Advisors LLC Takes Position in Pfizer Inc. (NYSE:PFE)

Key Points

• American Alpha Advisors LLC purchased 16,504 shares of Pfizer Inc., valued at approximately $418,000, marking a new investment during the first quarter.
• Analysts have varying opinions on Pfizer's stock, with recent price target adjustments ranging from a decrease to $26.00 by Leerink Partners to an increase to $26.00 by Citigroup.
• Pfizer recently declared a $0.43 quarterly dividend, reflecting a 7.0% yield and a high payout ratio of 91.49%.

American Alpha Advisors LLC acquired a new stake in Pfizer Inc. (NYSE:PFE - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 16,504 shares of the biopharmaceutical company's stock, valued at approximately $418,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of PFE. William B. Walkup & Associates Inc. raised its stake in Pfizer by 1.2% in the 4th quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company's stock worth $1,044,000 after purchasing an additional 454 shares in the last quarter. Members Trust Co raised its stake in Pfizer by 2.1% in the 1st quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company's stock worth $587,000 after purchasing an additional 467 shares in the last quarter. Sutton Place Investors LLC raised its stake in Pfizer by 5.6% in the 1st quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company's stock worth $224,000 after purchasing an additional 472 shares in the last quarter. Bellevue Group AG raised its position in shares of Pfizer by 0.3% in the 4th quarter. Bellevue Group AG now owns 141,560 shares of the biopharmaceutical company's stock valued at $3,756,000 after buying an additional 485 shares in the last quarter. Finally, Gould Capital LLC raised its position in shares of Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 493 shares in the last quarter. Institutional investors own 68.36% of the company's stock.

Pfizer Trading Up 1.6%

PFE traded up $0.39 during trading on Wednesday, reaching $25.04. 27,130,985 shares of the company's stock were exchanged, compared to its average volume of 45,751,281. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $142.34 billion, a PE ratio of 13.32, a price-to-earnings-growth ratio of 0.88 and a beta of 0.52. The firm has a fifty day moving average price of $24.49 and a two-hundred day moving average price of $24.47.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period in the previous year, the firm posted $0.60 EPS. The company's revenue for the quarter was up 10.3% compared to the same quarter last year. As a group, equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio is currently 91.49%.

Wall Street Analyst Weigh In

Several brokerages have recently commented on PFE. Citigroup boosted their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. The Goldman Sachs Group boosted their target price on shares of Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. HSBC dropped their target price on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research report on Monday, May 19th. TD Cowen dropped their target price on shares of Pfizer from $32.00 to $28.00 and set a "hold" rating for the company in a research report on Tuesday, April 22nd. Finally, BMO Capital Markets lowered their price objective on shares of Pfizer from $36.00 to $30.00 in a research report on Thursday, April 17th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Pfizer presently has a consensus rating of "Hold" and an average target price of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.